New drug cocktail shows promise in rare colorectal cancer
NCT ID NCT05510895
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of three drugs (encorafenib, binimetinib, and cetuximab) given before surgery to people with a specific type of colorectal cancer that has a BRAF V600E mutation. Only 2 patients took part. The goal was to see how much the tumor shrank and to check for side effects. The results help guide future research, but the small size means we cannot draw broad conclusions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAF V600 MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hämatologisch-Onkologische Praxis Eppendorf
Hamburg, 20249, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Digital nurse companion: could an app ease the burden of chronic illness?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?